Get exclusive access to our latest content as soon as it's filmed for free at https://www.healthtree.org/aml/university
HealthTree University for acute myeloid leukemia offers a comprehensive online curriculum with lessons, quizzes and course discussion. Create a free account today to track your progress, earn points to win prizes, and stay up to date on the latest advancements in treating AML!

Topics covered include: AML basics, allogeneic stem cell transplant, AML genetics, relapsed and refractory AML and much more. We've partnered with AML experts to help you learn quickly. Improve the way you navigate your disease and obtain better outcomes with HealthTree University.

Stay up to date on the latest AML news through our newsletter! https://healthtree.org/aml/community/newsletter

Follow HealthTree:
Twitter: https://www.twitter.com/HealthTreeAML
Facebook: https://www.facebook.com/HealthTreeForAML
Instagram: https://www.instagram.com/healthtreeforaml

Minimal residual disease (MRD) after therapy has unequivocal prognostic value in acute myeloid leukemia. There is growing evidence that the presence of MRD detected by multiparametric flow cytometry (MFC) and quantitative polymerase chain reaction (qPCR)-based methods, has improved the assessment of treatment response and risk stratification for clinical management. New molecular methods, such as high-throughput next-generation sequencing (NGS), have evolved into routine laboratory tools to improve the sensitivity and specificity of MRD detection. In this talk, Dr. Chen reviews the methodological approaches of MRD detection, discusses the clinical implications of MRD in risk stratification and suggests potential areas for future investigation.

After viewing this lecture, participants should be able to:
1. Describe the methodological principles of minimal residual disease testing in acute myeloid leukemia.
2. Recognize the advantages and limitation of different methods for minimal residual disease testing.
3. Discuss the implications of minimal residual disease in prognosis and treatment of acute myeloid leukemia.

Xueyan Chen, MD, PhD, assistant professor, Department of Laboratory Medicine, associate director, Hematopathology Laboratory, UW

10/10/2017

http://depts.washington.edu/la....bweb/Education/ContE
http://uwtv.org

This Blood Drop video is part of a series of ignite presentations given at the American Society of Hematology’s, ASH-a-Palooza. ASH-a-Palooza is an educational experience that offers a relaxed, open learning environment for trainees with multiple opportunities for micro-learning.

https://www.hematology.org/ASH-a-Palooza

The Blood Drop presentation series covers a range of topics including hemostasis and thrombosis, sickle cell disease, ASH awards, wellness and quality improvement. Each presentation is given by an expert in their field and are presented at the event in person. If you missed any of the presentations, or the event itself, make sure to make it a part of your ASH schedule next year!

Link : www.genedent.com

Narration by : Geetika Raj ( Scientific Co-ordinator at Kroynas)

What is it?

Acute myeloid leukemia (AML) is a type of cancer that affects the blood and bone marrow, where blood cells are produced. In AML, abnormal blood cells, usually immature white blood cells called myeloblasts, rapidly accumulate in the bone marrow and interfere with the production of normal blood cells, such as red blood cells and platelets.

What are its causes?

The exact cause of AML is unknown, but several factors can increase the risk of developing the disease. These include exposure to radiation, chemicals such as benzene, certain chemotherapy drugs, smoking, and certain genetic disorders.

What are the genes behind it?

AML is associated with mutations in genes that regulate the growth and differentiation of blood cells. Some of the most common genes mutated in AML include FLT3, NPM1, and CEBPA. Mutations in these genes can lead to uncontrolled growth and accumulation of abnormal blood cells.

What are its symptoms?

The symptoms of AML can vary depending on the stage and severity of the disease. Common symptoms include fatigue, weakness, shortness of breath, fever, unexplained weight loss, easy bruising or bleeding, and frequent infections. Some patients may also experience bone pain, swollen lymph nodes, or an enlarged spleen.

What is its treatment?

The treatment of AML typically involves chemotherapy to kill cancer cells and promote the growth of healthy blood cells. Depending on the subtype and stage of the disease, other treatments may include radiation therapy, targeted therapy, or stem cell transplant. The choice of treatment depends on several factors, including the patient's age, overall health, and genetic profile. AML can be a difficult disease to treat, and the prognosis varies depending on several factors, including the subtype and stage of the disease, the patient's age, and overall health.

This video segment serves as a short introduction and educational lesson for our MedNet21 webcast on Acute and Chronic Myeloid Leukemia. The CME webcast can be viewed in its entirety at https://ccme.osu.edu/WebCastSearch.aspx. Enjoy this on-line education.

For just $1/month, you can help keep these videos free! Subscribe to my Patreon at http://www.patreon.com/pwbmd

(Disclaimer: The medical information contained herein is intended for physician medical licensing exam review purposes only, and are not intended for diagnosis of any illness. If you think you may be suffering from any medical condition, you should consult your physician or seek immediate medical attention.)